Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Delftia TsuruhatensTC1 Based-Intervention For Interrupting Malaria Transmission In Mosquitoes: A Novel Trial For Evaluating Alternative Tools For Control Of Vector-Borne Diseases

Project description

A new front in the fight against malaria

Malaria eradication is challenged by the rapid spread of insecticide‑resistant mosquitoes. A new strategy using the bacterium Delftia tsuruhatensis TC1 and its secreted compound Harmane blocks malaria parasite development in mosquitoes without affecting their survival, reducing the risk of resistance. Extensive laboratory and semi‑field studies show TC1 is effective, safe and manufacturable. However, existing WHO regulatory pathways, designed for insecticides, do not accommodate interventions targeting human‑to‑mosquito transmission. Traditional cluster randomised trials are increasingly difficult and costly due to growing heterogeneity and smaller effect sizes. The EU-funded DEFEND project will develop a novel trial design using entomological metrics to evaluate TC1’s impact in open‑field settings in Burkina Faso and Senegal, accelerating regulatory approval and deployment of next‑generation transmission‑blocking tools.

Objective

Malaria eradication efforts are severely hampered by the rapid emergence and spread of resistance in mosquitoes due to widespread use of insecticide-based vector-control tools. Recently, we have published a study proposing a novel malaria intervention strategy based on the use of a bacterial strain, Delftia tsuruhatensis TC1 (TC1 for short) and its secreted active component, Harmane (HA). The TC1-intervention interrupts malaria parasite development in mosquitoes without affecting mosquito survival and fitness thereby circumventing selection of resistant mosquitoes. Extensive studies to evaluate efficacy, safety and manufacturability have been successfully completed in both, laboratory and contained semi-field settings and further validate use of the TC1-intervention for malaria control.
Although, WHO has established product evaluation pathways and regulatory pipelines for insecticide-based vector control tools these are not suited for TC1 and other ‘TC1-like’ control strategies which do not fall within the ‘main-stream’ conventional category of malaria vector-control tools. To date all vector control tools have been evaluated in cluster randomized control trials (RCTs) to demonstrate epidemiological benefit but RCTs are becoming increasingly difficult and extremely expensive to conduct as standard-of-care increases the heterogeneity between clusters, diminishes the effect size of novel interventions thereby requiring higher numbers of clusters to reliably power studies. An urgent need exists for rigorous and validated entomological metrics which infer epidemiological benefit. This project aims to develop a novel trial for generating the evidence base of the TC1-intervention in open-field settings at the scale of the individual mosquito, to help support the regulatory process and expedite the time between product development and widespread deployment. Additionally, this novel trial could be extrapolated to similar interventions for controlling vector-borne diseases.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-01-two-stage

See all projects funded under this call

Coordinator

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Net EU contribution
€ 1 075 105,00
Address
C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD
28760 TRES CANTOS MADRID
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 075 105,00

Participants (3)